Search results
Results from the WOW.Com Content Network
In December 2017, Boehringer Ingelheim Pharmaceuticals Inc. agreed to pay $13.5 million to settle claims by all 51 state attorneys general (of the 50 states plus the Attorney General of the District of Columbia) that it engaged in off-label promotion of its drugs Aggrenox, Atrovent and Combivent, and Micardis. [57]
Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine synthesis in the substantia nigra of the brain .
Print/export Download as PDF; ... Pages in category "Drugs developed by Boehringer Ingelheim" ... This page was last edited on 4 October 2024, ...
March 7, 2024 at 6:07 AM (Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1 ...
And Boehringer Ingelheim is making it available to all Americans, regardless of insurance status," Gemmell said. Cyltezo will sell for $550, a 92% discount from the Humira list price of about $7,000.
The company said that, “contrary to what is presented in the (HELP) Committee’s letter,” it provides discounts and rebates of 70% off the list price of its inhaler products to insurers and ...
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!